Splenic Marginal Zone Lymphoma (DBCOND0028622)

Identifiers

Synonyms
Splenic marginal zone lymphomas / Splenic marginal zone lymphoma / Small cell B-cell lymphoma / Marginal zone lymphoma of spleen (disorder) / Splenic marginal zone B-cell lymphoma (disorder) / Splenic marginal zone lymphoma NOS / Splenic marginal zone B-cell lymphoma (morphologic abnormality) / Splenic lymphoma with villous lymphocytes (disorder)

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT05544019
Study of SGR-1505 in Mature B-Cell NeoplasmsNo drug interventionstreatment1recruiting
NCT05735834
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patientstreatment3recruiting
NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancersupportive_careNot Availablecompleted
NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphomatreatment1completed
NCT00082784
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasmstreatment1completed
NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphomatreatment1terminated
NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancertreatment1 / 2completed
NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaNo drug interventionstreatment2completed
NCT00054483
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunctionbasic_science1completed
NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgerytreatment1completed
NCT01045928
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1terminated
NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphomatreatment2completed
NCT00110071
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphomatreatment1completed
NCT01558778
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_careNot Availablewithdrawn
NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancerstreatment1completed
NCT00082888
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphomatreatment2completed
NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphomatreatment1completed
NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomatreatment1terminated
NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropeniatreatment1completed
NCT00068315
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemiatreatment1completed
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomastreatment1 / 2terminated
NCT00566332
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemiatreatment3completed
NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT01239875
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphomatreatment0completed
NCT00003970
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphomatreatment1completed
NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphomatreatment1active_not_recruiting
NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancertreatmentNot Availablecompleted
NCT01815749
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaNo drug interventionstreatment1active_not_recruiting
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomastreatment1 / 2active_not_recruiting
NCT01384513
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignanciestreatment2completed
NCT00073918
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphomatreatment2completed
NCT02049541
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphomatreatment1completed
NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplanttreatment1 / 2completed
NCT01720758
Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciestreatmentNot Availablecompleted
NCT01093586
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumorstreatment1completed
NCT00026182
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphomatreatment2completed
NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT00058227
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphomatreatment1completed
NCT00089076
MDX-010 in Treating Patients With Recurrent or Refractory Lymphomatreatment1 / 2terminated
NCT00098891
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomastreatment1completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00010192
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancertreatment1completed
NCT00101244
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphomatreatment1terminated
NCT01682044
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphomatreatment2completed
NCT01159067
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overloadsupportive_care2terminated
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00891072
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgerytreatment1completed
NCT02254772
A Phase I/II Study of Intratumoral Injection of SD-101treatment1 / 2completed
NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignanciestreatment2completed
NCT00060112
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphomatreatment1terminated
NCT03697512
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomastreatment2active_not_recruiting
NCT00003210
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Diseasetreatment2completed
NCT00088881
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphomatreatment2terminated
NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplantsupportive_careNot Availablecompleted
NCT00005950
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphomatreatment2terminated
NCT01523223
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignanciestreatment1completed
NCT00019708
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphomatreatment1terminated
NCT01678443
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignanciestreatment1terminated
NCT01408043
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomatreatmentNot Availableterminated
NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphomatreatment1 / 2completed
NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumorstreatment1 / 2completed
NCT02281279
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphomatreatment1 / 2withdrawn
NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphomatreatment1 / 2completed
NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplanttreatment0completed
NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphomatreatment2completed
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancertreatment2terminated
NCT00012298
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphomatreatment1 / 2terminated
NCT00343798
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignanciestreatment1completed
NCT00058305
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantationtreatment2completed
NCT01812005
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomatreatment2terminated
NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsNo drug interventionssupportive_care3completed
NCT00711828
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphomatreatment2completed
NCT01769911
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomatreatmentNot Availablewithdrawn
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00499811
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunctiontreatment1completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT00089271
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomastreatment1completed
NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisorderstreatmentNot Availablecompleted
NCT00769288
FAU in Treating Patients With Advanced Solid Tumors or LymphomaNo drug interventionstreatment1completed
NCT02168907
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomatreatment1terminated
NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomatreatmentNot Availablecompleted
NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1completed
NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaNo drug interventionsbasic_scienceNot Availablecompleted
NCT01701232
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphomatreatment3completed
NCT00621452
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphomatreatment1completed
NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciestreatmentNot Availableterminated
NCT00118170
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Functiontreatment1completed
NCT00601718
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphomatreatment1 / 2completed
NCT02945319
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone LymphomaNo drug interventionsNot AvailableNot Availablecompleted
NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaNo drug interventionstreatment1completed
NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanciestreatment1completed
NCT00004241
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcomatreatment1completed
NCT02109224
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infectiontreatment1terminated
NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomatreatmentNot Availablecompleted
NCT00720135
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1completed
NCT01110135
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myelomatreatment2completed
NCT00005786
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiatreatmentNot Availableterminated
NCT00054639
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphomatreatment2completed
NCT01769222
Ipilimumab and Local Radiation for Selected Solid Tumorstreatment1terminated
NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignanciessupportive_care2completed
NCT04223765
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.treatment1recruiting
NCT00458731
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytomatreatment1completed
NCT00275080
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemiatreatment1completed
NCT00438880
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphomatreatment1 / 2completed
NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphomatreatment2completed
NCT00119392
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphomatreatment2completed
NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1 / 2terminated
NCT00536601
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorstreatmentNot Availablecompleted
NCT00290472
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemiatreatment2completed
NCT00103272
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancertreatment1terminated
NCT00017472
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemiatreatment1completed
NCT00795769
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplantsupportive_care2completed
NCT01238146
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphomatreatment1 / 2withdrawn
NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignanciestreatment2completed
NCT01419795
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplanttreatment2terminated
NCT00072514
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignanciestreatment2completed
NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2withdrawn
NCT00244855
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphomatreatment2completed
NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignanciessupportive_care2completed
NCT00077155
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myelomatreatment1 / 2terminated
NCT03288415
SMZL Molecular Prognostic IndexNo drug interventionsNot AvailableNot Availableactive_not_recruiting